Status:
COMPLETED
The Roles of Tissue Factor in Malignant Gliomas
Lead Sponsor:
Ontario Clinical Oncology Group (OCOG)
Collaborating Sponsors:
Ontario Cancer Research Network
Conditions:
Venous Thromboembolism
Brain Tumors
Eligibility:
All Genders
18+ years
Brief Summary
To explore the relationship between tissue factor levels, tumour progression, activation of blood coagulation and venous thromboembolism with malignant glioma
Detailed Description
To explore the relationship between tissue factor levels, tumour progression, activation of blood coagulation and venous thromboembolism with malignant glioma
Eligibility Criteria
Inclusion
- participation in PRODIGE
- adult patients
- newly diagnosed, biopsy-confirmed grade III/IV malignant gliomas
- undergone craniotomy or stereotactic biopsy \> 2 days and \< 4 weeks before
Exclusion
- have known hereditary thrombophilia
- are receiving experimental antiangiogenic therapy
Key Trial Info
Start Date :
January 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2006
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00201903
Start Date
January 1 2004
End Date
October 1 2006
Last Update
April 6 2017
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Henry Ford Hospital
Detroit, Michigan, United States, 48202
2
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112-5550
3
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
4
CancerCare Manitoba
Winnipeg, Manitoba, Canada, R3E 0V9